Résumé
Objective To investigate the clinical effect of targeted drug therapy for non-small cell lung cancer.MethodsThe study group received gefitinib targeted drug therapy, the control group was given erlotinib treatment, recording two groups of patients with non-small cell lung cancer, survival time, follow-up treatment costs and adverse reaction incidence (drug).ResultsThe total efficiency of treatment (37.50%) and the control group (the total efficiency of treatment 35.42%) no obvious difference;no significant difference between the survival time of patients in group two non-small cell lung cancer, but the study group treatment costs significantly less than the control group (P<0.05);two groups of patients with non-small cell lung cancer were treated with erlotinib and gefitinib poisoning reaction contrast did not significant difference.ConclusionGefinitib targeted therapy of non-small cell lung cancer can be based on protecting the clinical curative effect and prognosis of the patients, reduce the economic pressure, more conducive to the positive reception and treatment.